The Intralesional Use of Triamcinolone Acetonide in PsoriasisA Double Blind Study
J. HASEGAWA, M.D.;
W. LIVINGSTON, M.D.
Arch Dermatol. 1962;85(2):258-260.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
The effectiveness of the treatment of psoriatic lesions by the intralesional injections of triamcinolone acetonide has been demonstrated by many investigators.1-3 In a double blind study of psoriatic patients triamcinolone acetonide by intralesional injection was indeed found to be effective in clearing the lesion of psoriasis. Its efficacy was markedly greater than hydrocortisone or prednisolone tertiary butyl acetate.
Material and Method
All patients in this study were hospitalized and had no other form of systemic or topical therapy. In order to avoid the possibility of systemic effect the amount of triamcinolone acetonide injected was limited to 0.2 ml. of 1% suspension. The control material was the vehicle alone to which hydrocortisone acetate was added to make a 0.4% suspension to simulate the cloudy appearance of the triamcinolone acetonide suspension. Hydrocortisone acetate in this concentration was found to be totally ineffective in the treatment of psoriatic plaques. The suspensions were
. . . [Full Text PDF of this Article]
Author Affiliations
CHICAGO
From the Department of Dermatology of the Northwestern University Medical Center (H. Rattner, M.D., Chairman) and the Department of Medicine (Dermatology) of the Veterans Administration Research Hospital.
Footnotes
Submitted for publication Sept. 11, 1961.
This study was supported in part by a grant from the Squibb Institute for Medical Research.
Triamcinolone acetonide (Kenalog) and the diluent were supplied by the Squibb Institute for Medical Research.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
